A research team led by Professor Kim Kwang-pyo of Kyung Hee University's Department of Applied Chemistry has developed a next ...

Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of ...

The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer. LAUSANNE, Switzerland, April 28, 2025/ ...

Noul Co., Ltd. (CEO: David Lim), a company specializing in AI-powered blood and cancer diagnostics, today announced that it ...

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...

It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer. Age and insurance status were ...